Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610618-23-000030
Filing Date
2023-03-29
Accepted
2023-03-29 17:26:42
Documents
2
Period of Report
2023-03-27

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_168012518825174.html 4  
1 FORM 4 wf-form4_168012518825174.xml 4 6345
2 POWER OF ATTORNEY, TARI a2022cidara-section16poale.htm EX-24 3486
  Complete submission text file 0001610618-23-000030.txt   11363
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CIDARA THERAPEUTICS, INC. 6310 NANCY RIDGE DR SUITE 101 SAN DIEGO CA 92121
Business Address
Tari Leslie (Reporting) CIK: 0001870270 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36912 | Film No.: 23776276